Orlistat

Orlistat (Tetrahydrolipstatin) is a well-known irreversible inhibitor of pancreatic and gastric lipases. Orlistat is also an inhibitor of fatty acid synthase (FASN), is used orally for long-term research of obesity[1]. Anti-atherosclerotic effect[2].

Product Specifications

CAS Number

[96829-58-2]

Product Name Alternative

Tetrahydrolipstatin; Ro-18-0647

UNSPSC

12352005

Hazard Statement

H302, H412

Target

Apoptosis; Fatty Acid Synthase (FASN)

Type

Reference compound

Related Pathways

Apoptosis; Metabolic Enzyme/Protease

Applications

Cancer-programmed cell death

Field of Research

Metabolic Disease; Cancer

Assay Protocol

https://www.medchemexpress.com/orlistat.html

Concentration

10mM

Purity

99.95

Solubility

DMSO : 100 mg/mL (ultrasonic) |H2O : < 0.1 mg/mL

Smiles

O=C1[C@@H](CCCCCC)[C@H](C[C@@H](OC([C@@H](N([H])C([H])=O)CC(C)C)=O)CCCCCCCCCCC)O1

Molecular Formula

C29H53NO5

Molecular Weight

495.73

Precautions

H302, H412

References & Citations

[1]Giorgia Cioccoloni, et al. Influence of fatty acid synthase inhibitor orlistat on the DNA repair enzyme O6-methylguanine-DNA methyltransferase in human normal or malignant cells in vitro. Int J Oncol. 2015 Aug;47 (2) :764-72.|[2]Zaidatul Akmal Othman, et al. Anti-Atherogenic Effects of Orlistat on Obesity-Induced Vascular Oxidative Stress Rat Model. Antioxidants (Basel) . 2021 Feb 6;10 (2) :251.